Experimental drug offers hope for cancer patients with depleted immune cells

NCT ID NCT06956547

AVAILABLE Disease control Sponsor: ImmunityBio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This expanded access program provides nogapendekin-alfa inbakicept (NAI) to adults with solid tumors who have low lymphocyte counts caused by prior cancer treatments like chemotherapy, immunotherapy, or radiation. The goal is to reverse and maintain healthy lymphocyte levels. It is for patients who cannot join a clinical trial and will receive NAI injections every 2-3 weeks alongside their standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nogapendekin-alfa inbakicept (NAI)
What this could lead to: If it works, this could help restore immune cell levels in cancer patients whose lymphocyte counts dropped due to chemotherapy, immunotherapy, or radiation.
What could go wrong: This is an expanded access program, not a formal trial, so results are not systematically collected. It is only for patients who cannot join a clinical trial, and benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphopenia neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOPENIA

Contacts and locations

Locations

Chan Soon - Shiong Institute for Medicine
AVAILABLE

El Segundo, California, 90245, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.